이바플록사신

항생제 - 플루오로퀴놀론계

이바플록사신은 주로 유럽에서 사용되는 수의학 전용 경구용 **플루오로퀴놀론계 항생제**입니다(미국 미승인). 그람 음성균 및 일부 그람 양성균(장내세균과, 포도상구균 등)에 대해 **농도 의존적 살균 효과**를 나타냅니다. > **임상 요점**: 다른 플루오로퀴놀론계(엔로플록사신, 마보플록사신 등)와 달리 녹농균, 연쇄상구균, 프로테우스 미라빌리스에 대한 효과는 떨어집니다. 고양이에서 **망막 독성을 유발한다는 보고가 없다는 점**은 이 계열의 다른 약물에 비해 큰 장점입니다.

작용 기전: Fluoroquinolones exert their bactericidal effect by targeting essential bacterial enzymes involved in DNA replication and transcription. * **Primary Target**: Inhibits **bacterial DNA-gyrase** (topoisomerase II) → prevents DNA supercoiling → halts DNA synthesis. * **Secondary Target**: Inhibits **topoisomerase IV** → interferes with the separation of interlinked replicated DNA molecules. Ibafloxacin is metabolized into two active metabolites (8-hydroxy-ibafloxacin and 7-hydroxy-ibafloxacin), which contribute to its overall antimicrobial efficacy.

동물 종별 용량

Cats

Susceptible infections (dermal infections: soft tissue infections-wounds, abscesses; upper respiratory tract infections) · 15 mg/kg PO once daily · PO · q24h · Usually a 10-day course is sufficient. · Give at time of feeding. Reconsider treatment if no improvement after 5 days.

Dogs

Susceptible infections (dermal infections: superficial and deep pyoderma, wounds, abscesses) · 15 mg/kg PO once daily · PO · q24h · Usually a 10-day course is sufficient. In cases of deep pyoderma, reconsider treatment if sufficient improvement not seen in 21 days. · Give at time of feeding. Reconsider treatment if no improvement after 5 days.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

Dogs less than 8 months of age
Giant breed dogs less than 18 months of age
Cats less than 8 months of age
Known quinolone hypersensitivity

이상반응

Diarrhea
Soft feces
Vomiting
Dullness
Anorexia
Salivation
Elevated hepatic enzymes (rare, class effect)
Ataxia (rare, class effect)
Seizures (rare, class effect)
Depression/Lethargy (rare, class effect)
Nervousness (rare, class effect)

약물 상호작용

NSAIDs · Should not be used with NSAIDs in dogs with a history of seizures due to increased risk of CNS stimulation.
Antacids or Supplements (iron, zinc, magnesium, aluminum, calcium) · Cations may bind to ibafloxacin and prevent its gastrointestinal absorption.
Cyclosporine · Fluoroquinolones may exacerbate the nephrotoxicity of systemic cyclosporine.
Nitrofurantoin · May antagonize the antimicrobial activity of fluoroquinolones; concomitant use is not recommended.
Quinidine · Increased risk for cardiotoxicity.
Sucralfate · May inhibit absorption of ibafloxacin; separate doses by at least 2 hours.
Theophylline · Ibafloxacin may increase theophylline blood levels.

모니터링

Clinical efficacy
Adverse GI effects (vomiting, hypersalivation, diarrhea, anorexia)

과용량

Specific information is limited. It is unlikely an acute overdose would result in signs more serious than anorexia or vomiting. * **Dogs**: Doses of 75 mg/kg/day (5X) were apparently well tolerated. * **Cats**: Doses up to 75 mg/kg/day demonstrated salivation and vomiting. If overdose occurs in cats, ophthalmic monitoring is recommended as a precaution, despite no reported ocular toxicity.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.